Core Scientific, Inc./tx
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
CORZ$13.13+3.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(Unaudited, in thousands, except par value)
| September 30,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $803,941 | $311,378 |
| Digital assets | 2,690 | 222,000 |
| Customer funding receivable | 282,659 | 337,158 |
| Restricted cash, current portion | 201,745 | — |
| Other current assets | 131,115 | 25,001 |
| Total current assets | 1,422,150 | 895,537 |
| Property, plant and equipment, net | 2,630,353 | 1,293,299 |
| Intangibles, net | 737,531 | 1,076 |
| Operating lease right-of-use assets | 110,503 | 108,484 |
| Deferred lease incentive, net of current portion | 295,000 | — |
| Restricted cash, net of current portion | 635,858 | — |
| Other noncurrent assets | 104,319 | 49,248 |
| Total assets | $5,935,714 | $2,347,644 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $120,876 | $126,106 |
| Accrued expenses | 779,520 | 511,957 |
| Deferred revenue, current portion | 309,065 | 127,561 |
| Warrant liabilities, current portion | 880,725 | — |
| Other current liabilities | 17,028 | 15,777 |
| Total current liabilities | 2,107,214 | 781,401 |
| Long-term debt | 4,302,175 | 1,060,325 |
| Deferred revenue, net of current portion | 264,506 | 428,290 |
| Warrant liabilities, net of current portion | 238,180 | 936,107 |
| Other noncurrent liabilities | 115,717 | 104,261 |
| Total liabilities | 7,027,792 | 3,310,384 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ deficit: | ||
| Preferred stock; $0.00001 par value; 2,000,000 shares authorized; none issued and outstanding at September 30, 2026 and December 31, 2025 | — | — |
| Common stock; $0.00001 par value; 10,000,000 shares authorized at September 30, 2026 and December 31, 2025; 321,972 and 314,231 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 3 | 3 |
| Additional paid-in capital | 3,378,990 | 3,183,960 |
| Accumulated deficit | (4,471,071) | (4,146,703) |
| Total stockholders’ deficit | (1,092,078) | (962,740) |
| Total liabilities and stockholders’ deficit | $5,935,714 | $2,347,644 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.